Clinical trials: Vestibular Vertigo
Vestibular Disorder, Dizziness
Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability
The goal of this study is to evaluate a tactile prosthesis that provide individuals who have demonstrated chronic imbalance with help to maintain a correct sense of orientation with respect to the gravity and improve posture…
- Trial name
- BALCAP (NCT03330262)
- Testing
- BALCAP prosthesis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Barron Associates, Inc.
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-2 (NCT02717442)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Otonomy, Inc.
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Vertigo
Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice
The purposes of this international post-marketing observational program is to investigate effectiveness of betahistine dihydrochloride (Betaserc®) tablets and assess the course of vestibular vertigo after treatment…
- Trial name
- VIRTUOSO (NCT01759251)
- Where
- 24 sites in Russia, Ukraine
- Volunteers
- 309 people
- Sponsor
- Abbott
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-1 (NCT02612337)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
- Trial name
- NCT02603081
- Testing
- SPI-1005
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere Disease
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- NCT03664674
- Testing
- OTO-104
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 148 people
- Sponsor
- Otonomy, Inc.
Meniere Disease, Ménière
SPI-1005 for the Treatment of Meniere's Disease
The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial (RCT) with open-label extension study (OLE), of SPI-1005 in adult subjects with definite Meniere's disease with active symptoms within three…
- Trial name
- STOPMD-3 (NCT04677972)
- Testing
- Ebselen
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Vestibular Disorder, Balance; Distorted
Individualized Vestibular Rehabilitation for Elderly With Self-Management and Gaming Elements
The aim of this study is to test whether when using the Vestibular Rehabilitation App older patients perform rehabilitation in a similar manner as when directly instructed by a clinician.
- Conditions
- Vestibular Disorder, Balance; Distorted, Vestibular Diseases
- Trial name
- NCT05436067
- Testing
- Vestibular rehabilitation app, Traditional Physical Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CFD Research Corporation
Meniere's Disease
SPI-1005 for the Treatment of Patients With Meniere's Disease
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
- Trial name
- NCT03325790
- Testing
- 200mg SPI-1005 BID, 400mg SPI-1005 BID
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sound Pharmaceuticals, Incorporated